Advisors Preferred LLC Sells 4,994 Shares of Mesoblast Limited (NASDAQ:MESO)

Advisors Preferred LLC cut its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 78.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,409 shares of the company’s stock after selling 4,994 shares during the period. Advisors Preferred LLC’s holdings in Mesoblast were worth $29,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Strategic Financial Concepts LLC bought a new position in Mesoblast during the 4th quarter valued at $2,744,000. Jane Street Group LLC lifted its stake in Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after acquiring an additional 26,959 shares in the last quarter. XY Capital Ltd bought a new position in Mesoblast during the 3rd quarter valued at $244,000. Creative Planning bought a new position in Mesoblast during the 3rd quarter valued at $147,000. Finally, Clayton Financial Group LLC bought a new position in Mesoblast during the 4th quarter valued at $275,000. 1.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MESO. Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Piper Sandler reiterated an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday. Finally, Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mesoblast currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Price Performance

Shares of Mesoblast stock opened at $19.49 on Friday. Mesoblast Limited has a 52-week low of $1.75 and a 52-week high of $22.00. The stock’s 50-day simple moving average is $16.48 and its 200 day simple moving average is $11.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.